Teva Pharmaceutical Industries Ltd (NYSE:TEVA)announced that the U.S. Court of Appeals for the Federal Circuit upheld a ruling by the U.S. District Court for the District of Delaware finding Bristol-Myers Squibb’s entecavir compound claim of U.S. Patent No. 5,206,244 invalid. Teva’s ANDA for entecavir has received tentative approval from the U.S. Food and Drug Administration (FDA). Teva will finalize the launch plans for this product once it receives final approval from the FDA. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 1.76%. On last trading day company shares ended up $51.98. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 2.86%.
Biogen Idec Inc (NASDAQ:BIIB) shares advanced 0.06% in last trading session and ended the day on The approval this week of Biogen Idec’s second hemophilia drug cements the biotech’s entry into a disease field that has seen its share of setbacks in recent years. $309.98. Gross Margin is 86.90% and its return on assets is 16.60%. Biogen Idec Inc (NASDAQ:BIIB) quarterly performance is -6.77%.
AstraZeneca plc (ADR) (NYSE:AZN) announced that it has entered into an agreement with UK-based Synairgen to in-license its respiratory disease candidate, SNG001. SNG001 is being developed for the treatment of respiratory tract viral infections in patients suffering from severe asthma. AstraZeneca plc (ADR) (NYSE:AZN) shares moved up 0.27% in last trading session and was closed at $74.24, while trading in range of $73.87 – $74.39. AstraZeneca plc (ADR) (NYSE:AZN) year to date (YTD) performance is 28.64%.
On June 11, DAIICHI SANKYO CO LT (OTCMKTS:DSKYF) rose 1.7% to 1,765 yen after Mizuho Securities rose the company’s rating to buy from neutral, saying new products will drive earnings growth. DAIICHI SANKYO CO LT (OTCMKTS:DSKYF) ended the last trading day at $17.51 .
On June 3, ASTELLAS PHARMA INC (OTCMKTS:ALPMY) a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. (NASDAQ: MDVN) reported positive results form the Phase III PREVAIL trial of enzalutamide in men with progressive chemotherapy-naïve metastatic prostate cancer following luteinizing hormone-releasing hormone therapy or bilateral orchiectomy. ASTELLAS PHARMA INC (OTCMKTS:ALPMY) On last trading day company shares ended up $12.93 .